-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Txq07bIMguek4HnpFnu4X4PlNmrLTEb9jy1f77aKyRZDH6Y5DjZAz6PIlJBegJm2 njZIKP1nL/ug8s/TQZH8QA== 0001182473-04-000003.txt : 20040817 0001182473-04-000003.hdr.sgml : 20040817 20040817165044 ACCESSION NUMBER: 0001182473-04-000003 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20040813 FILED AS OF DATE: 20040817 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROSEN TERRY J CENTRAL INDEX KEY: 0001182473 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 333-89177 FILM NUMBER: 04982400 MAIL ADDRESS: STREET 1: C/O TULARK INC STREET 2: TWO CORP DRIVE S CITY: SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TULARIK INC CENTRAL INDEX KEY: 0000889057 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943148800 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1120 VETERANS BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6508257300 MAIL ADDRESS: STREET 1: 1120 VETERANS BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 edgar.xml PRIMARY DOCUMENT X0202 4 2004-08-13 1 0000889057 TULARIK INC TLRK 0001182473 ROSEN TERRY J C/O TULARIK INC. 1120 VETERANS BLVD. SO. SAN FRANCISCO CA 94080 0 1 0 0 Executive VP, Operations Common Stock 2004-08-13 4 D 0 87740 D 0 D Common Stock 2004-08-13 4 D 0 1034.357 D 0 I By 401(k) Trust Common Stock 2004-08-13 4 D 0 49998 D 0 I By Trust Common Stock 2004-08-13 4 D 0 50626 D 0 I By Family Trust Stock Option (right to buy) 3.00 2004-08-13 4 D 0 5000 D 2007-01-30 Common Stock 5000 0 D Stock Option (right to buy) 3.00 2004-08-13 4 D 0 8333 D 2007-06-09 Common Stock 8333 0 D Stock Option (right to buy) 3.00 2004-08-13 4 D 0 36083 D 2008-06-17 Common Stock 36083 0 D Stock Option (right to buy) 3.00 2004-08-13 4 D 0 40250 D 2009-03-11 Common Stock 40250 0 D Stock Option (right to buy) 18.50 2004-08-13 4 D 0 25000 D 2009-12-15 Common Stock 25000 0 D Stock Option (right to buy) 58.25 2004-08-13 4 D 0 20000 D 2010-02-09 Common Stock 20000 0 D Stock Option (right to buy) 25.375 2004-08-13 4 D 0 20000 D 2010-04-26 Common Stock 20000 0 D Stock Option (right to buy) 23.125 2004-08-13 4 D 0 20000 D 2010-06-07 Common Stock 20000 0 D Stock Option (right to buy) 33.0625 2004-08-13 4 D 0 20000 D 2010-09-20 Common Stock 20000 0 D Stock Option (right to buy) 28.00 2004-08-13 4 D 0 20000 D 2010-12-06 Common Stock 20000 0 D Stock Option (right to buy) 22.25 2004-08-13 4 D 0 75000 D 2011-04-19 Common Stock 75000 0 D Stock Option (right to buy) 14.40 2004-08-13 4 D 0 33334 D 2012-04-17 Common Stock 33334 0 D Stock Option (right to buy) 10.40 2004-08-13 4 D 0 33333 D 2012-05-16 Common Stock 33333 0 D Stock Option (right to buy) 6.86 2004-08-13 4 D 0 10000 D 2012-06-12 Common Stock 10000 0 D Stock Option (right to buy) 7.99 2004-08-13 4 D 0 33333 D 2012-06-17 Common Stock 33333 0 D Stock Option (right to buy) 4.88 2004-08-13 4 D 0 225000 D 2013-03-20 Common Stock 225000 0 D Total of non-derivative securities directly owned included 346 shares Tularik common stock acquired under Tularik's Employee Stock Purchase Plan on July 30, 2004. Disposed of pursuant to merger agreement between issuer and Amgen Inc. in exchange for 39,570 shares of Amgen common stock having a market value of $55.432 per share pursuant to the terms of the merger agreement. Total of non-derivative securities indirectly owned under the 401(k) Trust included 57.64 shares and 3.427 shares Tularik common stock acquired on March 31, 2004 and June 30, 2004, respectively. Disposed of pursuant to merger agreement between issuer and Amgen Inc. in exchange for 466 shares of Amgen common stock having a market value of $55.432 per share pursuant to the terms of the merger agreement. The reporting person disclaims beneficial ownership of such securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16, or for any other purpose. Disposed of pursuant to merger agreement between issuer and Amgen Inc. in exchange for 22,549 shares of Amgen common stock having a market value of $55.432 per share pursuant to the terms of the merger agreement. Disposed of pursuant to merger agreement between issuer and Amgen Inc. in exchange for 22,832 shares of Amgen common stock having a market value of $55.432 per share pursuant to the terms of the merger agreement. This option, which was fully vested on January 1, 2001, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 2,255 shares of Amgen common stock for $6.66 per share. This option, which was fully vested on June 9, 2001, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 3,758 shares of Amgen common stock for $6.66 per share. This option, which was fully vested on June 17, 2002, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 16,273 shares of Amgen common stock for $6.66 per share. This option, which was fully vested on June 15, 2003, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 18,152 shares of Amgen common stock for $6.66 per share. This option, which was fully vested on December 15, 2003, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 11,275 shares of Amgen common stock for $41.02 per share. This option, which was fully vested on February 9, 2004, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 9,019 shares of Amgen common stock for $129.16 per share. This option, which was fully vested on April 26, 2004, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 9,020 shares of Amgen common stock for $56.27 per share. This option, which was fully vested on June 7, 2004, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 9,020 shares of Amgen common stock for $51.28 per share. This option, which provided for monthly vesting beginning October 20, 2000 until full vest on September 20, 2004 was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 9,020 shares of Amgen common stock for $73.31 per share. This option, which provided for monthly vesting beginning January 6, 2000 until full vest on December 6, 2004 was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 9,020 shares of Amgen common stock for $62.09 per share. This option, which provided for monthly vesting beginning May 20, 2001 until full vest on April 20, 2005, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 33,824 shares of Amgen common stock for $49.34 per share. This option, which provided for monthly vesting beginning May 18, 2002 until full vest on April 18, 2006, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 15,032 shares of Amgen common stock for $31.93 per share. This option, which provided for monthly vesting beginning June 17, 2002 until full vest on May 17, 2006, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 15,032 shares of Amgen common stock for $23.06 per share. This option, which provided for monthly vesting over a four-year period beginning July 13, 2002 until full vest on June 13, 2006, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 4,509 shares of Amgen common stock for $15.22 per share. This option, which provided for monthly vesting over a four-year period beginning July 18, 2002 until full vest on June 18, 2006, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 15,032 shares of Amgen common stock for $17.72 per share. This option, which provided for monthly vesting beginning April 21, 2003 until full vest on March 21, 2007, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 101,474 shares of Amgen common stock for $10.83 per share. Valerie L. Pierce, as Attorney in Fact for Terry J. Rosen 2004-08-16 -----END PRIVACY-ENHANCED MESSAGE-----